This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Rahden, B. H.A. Articles by Sarbia, M. Search for Related Content PubMed PubMed Citation Articles by von Rahden, B. H.A. Articles by Sarbia, M.

Coexpression of Cyclooxygenases (COX-1, COX-2) and Vascular Endothelial Growth Factors (VEGF-A, VEGF-C) in Esophageal Adenocarcinoma

¹ Department of Surgery and ² Institute for Pathology and Pathologic Anatomy, Technical University of Munich, Munich, Germany

Requests for reprints: Burkhard H.A. von Rahden, Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr 22, D-81677 Munich, Germany. Phone: 49-894-140-4165; Fax: 49-894-140-4865; E-mail: vrahden{at}nt1.chir.med.tu-muenchen.de.

Cyclooxygenases (COX), especially COX-2, are considered to be involved in carcinogenesis. Our study was initiated to test whether expression of COX isoforms (COX-1 and COX-2) is linked to expression of potent inducers of angiogenesis [vascular endothelial growth factor (VEGF)-A] and lymphangiogenesis (VEGF-C) in esophageal adenocarcinoma. One hundred twenty-three esophageal adenocarcinomas were investigated by means of quantitative reverse transcription-PCR for expression of COX-1, COX-2, VEGF-A, and VEGF-C. Additionally, COX-2 protein expression was determined using immunohistochemistry. Three esophageal cancer cell lines (OE-33, OSC-1, and OSC-2) were treated with COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) and the effect on expression of the four genes was determined. COX-2 protein expression was found in all carcinomas under analysis. RNA expression levels of COX-1 and COX-2 varied markedly in carcinoma tissues and correlated significantly with each other (P < 0.001, r = 0.726). Furthermore, COX expression correlated with expression of VEGF-A (COX-1: P < 0.001, r = 0.753; COX-2: P < 0.001, r = 0.764) and VEGF-C (COX-1: P < 0.001, r = 0.778; COX-2: P < 0.001; r = 0.613). Exposure of esophageal cancer cell lines OE-33, OSC-1, and OSC-2 with three COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) resulted in significantly reduced expression of VEGF-A and VEGF-C. In conclusion, our data suggest that both COX isoforms may be involved in the pathogenesis of esophageal adenocarcinoma, as they are linked to the expression of important modulators of angiogenesis (VEGF-A) and lymphangiogenesis (VEGF-C).

This article has been cited by other articles:

				H. Kwak, I. Hwang, J. H. Kim, M. Y. Kim, J. S. Yang, and S. Jeong Modulation of transcription by the peroxisome proliferator-activated receptor {delta}-binding RNA aptamer in colon cancer cells Mol. Cancer Ther., September 1, 2009; 8(9): 2664 - 2673. [Abstract] [Full Text] [PDF]

				N. Baryawno, B. Sveinbjornsson, S. Eksborg, A. Orrego, L. Segerstrom, C. O. Oqvist, S. Holm, B. Gustavsson, B. Kagedal, P. Kogner, et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets Neuro-oncol, January 1, 2008; 10(5): 661 - 674. [Abstract] [Full Text] [PDF]

				D. Vallbohmer, J. H. Peters, H. Kuramochi, D. Oh, D. Yang, D. Shimizu, S. R. DeMeester, J. A. Hagen, P. T. Chandrasoma, K. D. Danenberg, et al. Molecular Determinants in Targeted Therapy for Esophageal Adenocarcinoma Arch Surg, May 1, 2006; 141(5): 476 - 482. [Abstract] [Full Text] [PDF]